Search Results - "Wollenberg, A."

Psychodermatological aspects of atopic dermatitis by Senra, M.S., Wollenberg, A.

“…Summary Psychodermatology is an evolving area of science that focuses on the interaction between the mind, skin and body. It is known that various…”
Get full text

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2) by Wollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J.‐P., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., Lesiak, A., Kircik, L., Cho, S.H., Herranz, P., Cork, M.J., Peris, K., Steffensen, L.A., Bang, B., Kuznetsova, A., Jensen, T.N., Østerdal, M.L., Simpson, E.L.

“…Summary Background Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin‐13, a key cytokine driving peripheral inflammation in…”
Get full text

Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I by Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., Czarnecka‐Operacz, M., Schäfer, T., Schmid‐Grendelmeier, P., Simon, D., Szalai, Z., Szepietowski, J.C., Taïeb, A., Torrelo, A., Werfel, T., Ring, J.

“…This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a…”
Get full text

Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II by Wollenberg, A., Barbarot, S., Bieber, T., Christen‐Zaech, S., Deleuran, M., Fink‐Wagner, A., Gieler, U., Girolomoni, G., Lau, S., Muraro, A., Czarnecka‐Operacz, M., Schäfer, T., Schmid‐Grendelmeier, P., Simon, D., Szalai, Z., Szepietowski, J.C., Taïeb, A., Torrelo, A., Werfel, T., Ring, J.

“…This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a…”
Get full text

A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease – strategies for optimizing treatment outcome by Eicher, L., Knop, M., Aszodi, N., Senner, S., French, L.E., Wollenberg, A.

“…Adherence describes how a patient follows a medical regime recommended by a healthcare provider. Poor treatment adherence represents a complex and challenging…”
Get full text

The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group by Alexander, H., Paller, A.S., Traidl‐Hoffmann, C., Beck, L.A., De Benedetto, A., Dhar, S., Girolomoni, G., Irvine, A.D., Spuls, P., Su, J., Thyssen, J.P., Vestergaard, C., Werfel, T., Wollenberg, A., Deleuran, M., Flohr, C.

“…Summary Patients with atopic dermatitis (AD) have an increased risk of bacterial skin infections, which cause significant morbidity and, if untreated, may…”
Get full text

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS) by Wollenberg, A., Beck, L.A., Blauvelt, A., Simpson, E.L., Chen, Z., Chen, Q., Shumel, B., Khokhar, F.A., Hultsch, T., Rizova, E., Rossi, A.B., Graham, N.M.H., Pirozzi, G., Lu, Y., Ardeleanu, M.

“…Summary Background Dupilumab [a monoclonal antibody blocking the shared receptor subunit for interleukin (IL)‐4 and IL‐13] is approved for patients aged ≥ 12…”
Get full text

Lesion environments direct transplanted neural progenitors towards a wound repair astroglial phenotype in mice by O’Shea, T. M., Ao, Y., Wang, S., Wollenberg, A. L., Kim, J. H., Ramos Espinoza, R. A., Czechanski, A., Reinholdt, L. G., Deming, T. J., Sofroniew, M. V.

“…Neural progenitor cells (NPC) represent potential cell transplantation therapies for CNS injuries. To understand how lesion environments influence transplanted…”
Get full text

Introduction to the Pierre Fabre supplement by Wollenberg, A.

Get full text

Proactive therapy of atopic dermatitis - an emerging concept by Wollenberg, A, Bieber, T

Get full text

The introduction of bedside ex vivo confocal microscopy during Mohs surgery of basal cell carcinoma: Patient and specialist benefit in an optimized healthcare environment by Leemans, G, Wollenberg, A, Gutermuth, J

Get full text

Nipple eczema: A systematic review and practical recommendations by Reynaert, V., Gutermuth, J., Wollenberg, A.

“…The nipple is the focal point of the human breast and serves important physiological, sexual, and aesthetic purposes. It can be affected by atopic, irritant,…”
Get full text

Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials by Simpson, E.L., Lacour, J.‐P., Spelman, L., Galimberti, R., Eichenfield, L.F., Bissonnette, R., King, B.A., Thyssen, J.P., Silverberg, J.I., Bieber, T., Kabashima, K., Tsunemi, Y., Costanzo, A., Guttman‐Yassky, E., Beck, L.A., Janes, J.M., DeLozier, A.M., Gamalo, M., Brinker, D.R., Cardillo, T., Nunes, F.P., Paller, A.S., Wollenberg, A., Reich, K.

“…Summary Background Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced atopic dermatitis (AD) severity in a phase II study with…”
Get full text

Conjunctivitis in dupilumab clinical trials by Akinlade, B., Guttman‐Yassky, E., Bruin‐Weller, M., Simpson, E.L., Blauvelt, A., Cork, M.J., Prens, E., Asbell, P., Akpek, E., Corren, J., Bachert, C., Hirano, I., Weyne, J., Korotzer, A., Chen, Z., Hultsch, T., Zhu, X., Davis, J.D., Mannent, L., Hamilton, J.D., Teper, A., Staudinger, H., Rizova, E., Pirozzi, G., Graham, N.M.H., Shumel, B., Ardeleanu, M., Wollenberg, A.

“…Summary Background Dupilumab blocks the shared receptor component for interleukin (IL)‐4 and IL‐13. It is approved in the U.S.A. for patients aged ≥ 12 years…”
Get full text

Guidelines for treatment of atopic eczema (atopic dermatitis) Part I by Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink-Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A.P., Schäfer, T., Schwennesen, T., Seidenari, S., Simon, D., Ständer, S., Stingl, G., Szalai, S., Szepietowski, J.C., Taïeb, A., Werfel, T., Wollenberg, A., Darsow, U.

“…The existing evidence for treatment of atopic eczema (atopic dermatitis, AE) is evaluated using the national standard Appraisal of Guidelines Research and…”
Get full text

Recurrent eczema herpeticum – a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients by Seegräber, M., Worm, M., Werfel, T., Svensson, A., Novak, N., Simon, D., Darsow, U., Augustin, M., Wollenberg, A.

“…Background Eczema herpeticum (EH) is a disseminated viral infection of eczematous skin disease with the herpes simplex virus. Knowledge on clinical…”
Get full text

Guidelines for treatment of atopic eczema (atopic dermatitis) Part II by Ring, J., Alomar, A., Bieber, T., Deleuran, M., Fink-Wagner, A., Gelmetti, C., Gieler, U., Lipozencic, J., Luger, T., Oranje, A.P., Schäfer, T., Schwennesen, T., Seidenari, S., Simon, D., Ständer, S., Stingl, G., Szalai, S., Szepietowski, J.C., Taïeb, A., Werfel, T., Wollenberg, A., Darsow, U.

“…The existing evidence for treatment of atopic eczema (atopic dermatitis, AE) is evaluated using the national standard Appraisal of Guidelines Research and…”
Get full text

Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials by Barbarot, S., Wollenberg, A., Silverberg, J. I., Deleuran, M., Pellacani, G., Armario-Hita, J. C., Chen, Z., Shumel, B., Eckert, L., Gadkari, A., Lu, Y., Rossi, A. B.

“…Dupilumab, a first-in-class therapy targeting the two key cytokines involved in the persistent underlying inflammatory pathway in atopic dermatitis (AD), is…”
Get full text

Atopic dermatitis - all you can do from the outside by Gelmetti, C., Wollenberg, A.

“…Summary Atopic dermatitis (AD) affects both the epidermal barrier and the immune system and, as such, therapy needs to address both. Skin cleansing supported…”
Get full text

ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children by Wollenberg, A., Christen‐Zäch, S., Taieb, A., Paul, C., Thyssen, J.P., Bruin‐Weller, M., Vestergaard, C., Seneschal, J., Werfel, T., Cork, M.J., Kunz, B., Fölster‐Holst, R., Trzeciak, M., Darsow, U., Szalai, Z., Deleuran, M., Kobyletzki, L., Barbarot, S., Heratizadeh, A., Gieler, U., Hijnen, D.J., Weidinger, S., De Raeve, L., Svensson, Å., Simon, D., Stalder, J.F., Ring, J.

“…Atopic dermatitis (AD) is a highly pruritic, chronic inflammatory skin disease. The diagnosis is made using evaluated clinical criteria. Disease activity and…”
Get full text